Novartis highlights overall M&A track record following MorphoSys impairment

Nicole DeFeudis

Editor

Novartis CEO Vas Narasimhan assured investors on Tuesday that it takes a careful, systematic approach to M&A after recording an $800 million impairment to its …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novartis highlights overall M&A track record following MorphoSys impairment

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

No­var­tis high­lights over­all M&A track record fol­low­ing Mor­phoSys im­pair­ment

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Novartis highlights overall M&A track record following MorphoSys impairment